Table 3.
Multivariable cox regression analysis of recurrence-free survival (RFS) and overall survival (OS) in patients with HCC with wide and narrow of margin before and after PSM.
| Variable | Wide margin | Narrow margin | ||||||
|---|---|---|---|---|---|---|---|---|
| RFS | OS | RFS | OS | |||||
| HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | |
| Before PSM | ||||||||
| Child-Pugh, B vs. A | 3.47(1.25-9.66) | .017 | — | — | — | — | — | — |
| ALT, U/L, ≥ vs. < 44 | 1.63(1.20-2.23) | .002 | 1.64(1.06-2.50) | .027 | — | — | — | — |
| NLR, > vs. ≤2.5 | — | — | — | — | 1.51(1.09-2.09) | 0.014 | 1.76(1.19-2.61) | .005 |
| Tumor diameter, > vs. ≤5 cm | 1.89(1.38-2.58) | <.001 | 1.97(1.28-3.05) | .002 | — | — | — | — |
| MVI, positive vs. negative | 1.88(1.36-2.60) | <.001 | 2.42(1.55-3.78) | <.001 | 1.83(1.32-2.55) | <0.001 | 1.87(1.25-2.80) | .002 |
| TACE, yes vs. no | — | — | — | — | 0.77(0.56-0.95) | 0.035 | 0.60(0.40-0.89) | .011 |
| After PSM | ||||||||
| HBsAg, positive vs. negative | 2.15(1.07-4.31) | .031 | — | — | — | — | — | — |
| PT, ≥ vs. <13 s | 2.50(1.45-4.31) | .001 | 2.18(1.11-4.27) | .023 | — | — | — | — |
| Type of operation, major vs. minor | — | — | — | — | 1.77(1.06-2.96) | 0.028 | — | — |
| Transfusion, yes vs. no | — | — | — | — | — | — | 1.89(1.10-3.24) | .020 |
| Tumor diameter, > vs. ≤ 5 cm | 2.27(1.50-3.43) | <.001 | 2.17(1.26-3.76) | .006 | — | — | — | — |
| MVI, positive vs. negative | 1.80(1.18-2.73) | .006 | 2.59(1.48-4.53) | .001 | 1.72(1.13-2.61) | 0.012 | 1.66(1.01-2.71) | .043 |
| TACE, yes vs. no | — | — | — | — | 0.65(0.43-1.00) | 0.048 | 0.59(0.36-0.97) | .037 |
Bold values indicate statistical significance (P < 0.05).
Abbreviations: ALT, alanine aminotransferase; HCC, hepatocellular carcinoma; NLR, neutrophil-to-lymphocyte ratio; OS, overall survival; PSM, propensity score matching; TACE, transcatheter arterial chemoembolization.